Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pneumonia, Ventilator-Associated | 88 | 2024 | 279 | 25.130 |
Why?
|
Sepsis | 76 | 2024 | 2585 | 11.590 |
Why?
|
Cross Infection | 61 | 2024 | 1422 | 10.260 |
Why?
|
Infection Control | 41 | 2023 | 981 | 7.580 |
Why?
|
Shock, Septic | 25 | 2024 | 768 | 7.090 |
Why?
|
Respiration, Artificial | 50 | 2024 | 2628 | 6.170 |
Why?
|
Anti-Bacterial Agents | 65 | 2024 | 7407 | 4.640 |
Why?
|
Ventilators, Mechanical | 20 | 2022 | 288 | 4.560 |
Why?
|
Intensive Care Units | 52 | 2024 | 3745 | 3.980 |
Why?
|
Population Surveillance | 34 | 2024 | 2598 | 3.790 |
Why?
|
Respiratory Tract Infections | 8 | 2024 | 1010 | 3.540 |
Why?
|
Electronic Health Records | 39 | 2024 | 4811 | 3.230 |
Why?
|
Pneumonia | 15 | 2023 | 2143 | 3.100 |
Why?
|
Hospitals | 49 | 2024 | 3882 | 2.750 |
Why?
|
Chlorhexidine | 8 | 2022 | 160 | 2.560 |
Why?
|
Masks | 7 | 2023 | 208 | 2.530 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 7 | 2021 | 250 | 2.330 |
Why?
|
Virus Diseases | 5 | 2024 | 718 | 2.320 |
Why?
|
Anti-Infective Agents, Local | 6 | 2018 | 247 | 2.170 |
Why?
|
Community-Acquired Infections | 10 | 2024 | 469 | 2.070 |
Why?
|
Hospital Mortality | 28 | 2024 | 5294 | 1.990 |
Why?
|
Pneumonia, Viral | 11 | 2024 | 3204 | 1.950 |
Why?
|
Disease Transmission, Infectious | 5 | 2022 | 559 | 1.920 |
Why?
|
Critical Care | 21 | 2024 | 2696 | 1.860 |
Why?
|
Humans | 334 | 2024 | 761504 | 1.600 |
Why?
|
Aerosols | 7 | 2024 | 635 | 1.590 |
Why?
|
Influenza, Human | 9 | 2024 | 1521 | 1.520 |
Why?
|
Ventilator-Induced Lung Injury | 6 | 2021 | 120 | 1.490 |
Why?
|
Quality Indicators, Health Care | 9 | 2023 | 1792 | 1.480 |
Why?
|
Coronavirus Infections | 8 | 2020 | 3084 | 1.470 |
Why?
|
Massachusetts | 28 | 2024 | 8830 | 1.450 |
Why?
|
Antibiotic Prophylaxis | 4 | 2024 | 636 | 1.370 |
Why?
|
Communicable Diseases | 6 | 2021 | 875 | 1.340 |
Why?
|
Viruses | 2 | 2024 | 375 | 1.240 |
Why?
|
Communicable Disease Control | 3 | 2020 | 846 | 1.230 |
Why?
|
Respiratory Syncytial Virus Infections | 2 | 2023 | 366 | 1.220 |
Why?
|
Chlamydia Infections | 3 | 2021 | 365 | 1.210 |
Why?
|
Public Health Informatics | 3 | 2020 | 109 | 1.210 |
Why?
|
Drug Resistance, Multiple, Bacterial | 9 | 2021 | 587 | 1.200 |
Why?
|
Disease Notification | 6 | 2022 | 95 | 1.190 |
Why?
|
Sentinel Surveillance | 5 | 2023 | 291 | 1.180 |
Why?
|
Bacteremia | 5 | 2023 | 979 | 1.170 |
Why?
|
Health Personnel | 11 | 2024 | 3335 | 1.150 |
Why?
|
Lyme Disease | 2 | 2024 | 631 | 1.110 |
Why?
|
United States | 86 | 2024 | 72334 | 1.110 |
Why?
|
Pandemics | 20 | 2024 | 8654 | 1.110 |
Why?
|
Algorithms | 20 | 2024 | 14031 | 1.090 |
Why?
|
Critical Illness | 12 | 2023 | 2723 | 1.090 |
Why?
|
Quality Improvement | 11 | 2022 | 3801 | 1.090 |
Why?
|
Inappropriate Prescribing | 4 | 2022 | 211 | 1.060 |
Why?
|
Anti-Infective Agents | 6 | 2023 | 983 | 1.030 |
Why?
|
Intubation, Intratracheal | 6 | 2021 | 1329 | 1.030 |
Why?
|
Clostridium Infections | 5 | 2021 | 558 | 1.020 |
Why?
|
Gram-Negative Bacterial Infections | 3 | 2018 | 238 | 1.000 |
Why?
|
Behavioral Risk Factor Surveillance System | 4 | 2024 | 209 | 0.980 |
Why?
|
Mandatory Programs | 2 | 2022 | 86 | 0.910 |
Why?
|
Metapneumovirus | 1 | 2024 | 28 | 0.910 |
Why?
|
Laboratories | 2 | 2021 | 458 | 0.900 |
Why?
|
Paramyxoviridae Infections | 1 | 2024 | 57 | 0.900 |
Why?
|
Toothbrushing | 1 | 2024 | 46 | 0.890 |
Why?
|
Ralstonia pickettii | 1 | 2022 | 4 | 0.860 |
Why?
|
Burkholderia cepacia | 1 | 2022 | 22 | 0.840 |
Why?
|
Clinical Laboratory Techniques | 4 | 2020 | 746 | 0.830 |
Why?
|
Water Purification | 1 | 2023 | 60 | 0.830 |
Why?
|
Burkholderia cepacia complex | 1 | 2022 | 24 | 0.830 |
Why?
|
Bacterial Infections | 4 | 2021 | 1390 | 0.820 |
Why?
|
Benchmarking | 5 | 2023 | 1045 | 0.820 |
Why?
|
Burkholderia Infections | 1 | 2022 | 41 | 0.820 |
Why?
|
Retrospective Studies | 68 | 2024 | 80636 | 0.810 |
Why?
|
Hemorrhagic Fever, Ebola | 3 | 2016 | 420 | 0.770 |
Why?
|
Pseudomonas Infections | 2 | 2023 | 622 | 0.760 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2023 | 150 | 0.750 |
Why?
|
Veterans Health | 1 | 2023 | 215 | 0.750 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2022 | 1462 | 0.750 |
Why?
|
Hospitalization | 23 | 2024 | 10723 | 0.700 |
Why?
|
Benzodiazepines | 2 | 2016 | 1132 | 0.680 |
Why?
|
Air Microbiology | 1 | 2020 | 95 | 0.680 |
Why?
|
Adult | 84 | 2024 | 221177 | 0.680 |
Why?
|
Health Policy | 6 | 2022 | 2684 | 0.680 |
Why?
|
Gonorrhea | 2 | 2021 | 346 | 0.670 |
Why?
|
Oral Hygiene | 2 | 2017 | 132 | 0.670 |
Why?
|
Societies | 3 | 2019 | 108 | 0.660 |
Why?
|
Pneumonia, Bacterial | 3 | 2016 | 316 | 0.650 |
Why?
|
Delayed Diagnosis | 2 | 2020 | 463 | 0.650 |
Why?
|
Incidence | 27 | 2024 | 21353 | 0.650 |
Why?
|
Vancomycin | 2 | 2019 | 503 | 0.640 |
Why?
|
Insurance Claim Review | 2 | 2014 | 741 | 0.620 |
Why?
|
Mouthwashes | 2 | 2018 | 57 | 0.620 |
Why?
|
Male | 99 | 2024 | 360804 | 0.620 |
Why?
|
Delirium | 4 | 2018 | 1668 | 0.610 |
Why?
|
Daptomycin | 1 | 2018 | 71 | 0.610 |
Why?
|
Aged | 66 | 2024 | 169289 | 0.610 |
Why?
|
Female | 100 | 2024 | 392644 | 0.600 |
Why?
|
Indenes | 1 | 2018 | 59 | 0.590 |
Why?
|
Enterococcus faecium | 1 | 2018 | 101 | 0.590 |
Why?
|
Inhalation Exposure | 1 | 2020 | 432 | 0.580 |
Why?
|
Surgical Wound Infection | 4 | 2016 | 1527 | 0.570 |
Why?
|
Middle Aged | 75 | 2024 | 220895 | 0.570 |
Why?
|
Practice Guidelines as Topic | 17 | 2024 | 7390 | 0.570 |
Why?
|
Mass Screening | 4 | 2020 | 5428 | 0.560 |
Why?
|
Infectious Disease Transmission, Professional-to-Patient | 3 | 2022 | 33 | 0.550 |
Why?
|
Hepatitis B | 3 | 2013 | 705 | 0.550 |
Why?
|
Severity of Illness Index | 14 | 2022 | 15842 | 0.550 |
Why?
|
Risk Adjustment | 3 | 2021 | 600 | 0.540 |
Why?
|
Propensity Score | 1 | 2024 | 1913 | 0.540 |
Why?
|
Health Planning | 2 | 2014 | 230 | 0.540 |
Why?
|
Iatrogenic Disease | 1 | 2019 | 539 | 0.520 |
Why?
|
Clinical Coding | 5 | 2020 | 181 | 0.520 |
Why?
|
Catheter-Related Infections | 4 | 2024 | 273 | 0.510 |
Why?
|
Guideline Adherence | 5 | 2021 | 2220 | 0.510 |
Why?
|
Multiple Organ Failure | 6 | 2023 | 387 | 0.500 |
Why?
|
Universal Precautions | 1 | 2014 | 34 | 0.480 |
Why?
|
Government Regulation | 2 | 2022 | 524 | 0.480 |
Why?
|
Glottis | 1 | 2016 | 214 | 0.470 |
Why?
|
Risk Factors | 29 | 2024 | 74206 | 0.460 |
Why?
|
Workplace | 1 | 2020 | 863 | 0.460 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2012 | 942 | 0.460 |
Why?
|
Hypnotics and Sedatives | 3 | 2016 | 1179 | 0.460 |
Why?
|
Medicare | 8 | 2024 | 6770 | 0.450 |
Why?
|
Home Care Services | 2 | 2017 | 648 | 0.450 |
Why?
|
Patient Care Management | 2 | 2014 | 302 | 0.450 |
Why?
|
Occupational Exposure | 2 | 2021 | 1813 | 0.450 |
Why?
|
Ventilator Weaning | 1 | 2015 | 164 | 0.450 |
Why?
|
Length of Stay | 12 | 2024 | 6425 | 0.440 |
Why?
|
Respiratory Insufficiency | 2 | 2021 | 1230 | 0.440 |
Why?
|
Emergency Medical Services | 3 | 2022 | 1923 | 0.440 |
Why?
|
Time Factors | 16 | 2024 | 39967 | 0.430 |
Why?
|
Bronchoalveolar Lavage Fluid | 4 | 2020 | 755 | 0.430 |
Why?
|
Propofol | 2 | 2016 | 603 | 0.430 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 6 | 2024 | 698 | 0.420 |
Why?
|
Melatonin | 1 | 2018 | 669 | 0.420 |
Why?
|
Endocarditis | 1 | 2017 | 348 | 0.420 |
Why?
|
Drug Utilization | 1 | 2019 | 1188 | 0.420 |
Why?
|
Disease Outbreaks | 6 | 2023 | 1749 | 0.420 |
Why?
|
Hospital Administration | 1 | 2016 | 353 | 0.410 |
Why?
|
Observer Variation | 2 | 2016 | 2606 | 0.410 |
Why?
|
Critical Pathways | 1 | 2016 | 474 | 0.400 |
Why?
|
Respiratory Syncytial Viruses | 2 | 2024 | 168 | 0.400 |
Why?
|
Clinical Protocols | 2 | 2017 | 1440 | 0.400 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2014 | 343 | 0.400 |
Why?
|
Brain Injuries | 1 | 2024 | 2053 | 0.390 |
Why?
|
Occupational Diseases | 1 | 2020 | 1490 | 0.390 |
Why?
|
Prevalence | 14 | 2024 | 15732 | 0.390 |
Why?
|
Risk Management | 1 | 2015 | 558 | 0.390 |
Why?
|
Hepatitis A | 1 | 2012 | 128 | 0.390 |
Why?
|
Neuralgia, Postherpetic | 1 | 2011 | 41 | 0.380 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2015 | 494 | 0.380 |
Why?
|
Dexmedetomidine | 1 | 2016 | 319 | 0.380 |
Why?
|
Conscious Sedation | 1 | 2016 | 532 | 0.380 |
Why?
|
Emergency Service, Hospital | 6 | 2023 | 7879 | 0.350 |
Why?
|
Systemic Inflammatory Response Syndrome | 3 | 2024 | 621 | 0.340 |
Why?
|
Hospitals, Community | 1 | 2012 | 365 | 0.330 |
Why?
|
Ceftazidime | 3 | 2021 | 57 | 0.330 |
Why?
|
Decision Support Systems, Clinical | 2 | 2016 | 1175 | 0.320 |
Why?
|
Silver Compounds | 1 | 2008 | 23 | 0.320 |
Why?
|
Herpes Zoster | 1 | 2011 | 253 | 0.320 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2014 | 3415 | 0.310 |
Why?
|
Patient Compliance | 1 | 2019 | 2690 | 0.310 |
Why?
|
HIV Infections | 5 | 2024 | 17351 | 0.310 |
Why?
|
Academic Medical Centers | 6 | 2022 | 2759 | 0.300 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 2151 | 0.300 |
Why?
|
Pulmonary Edema | 3 | 2016 | 409 | 0.300 |
Why?
|
Urinary Tract Infections | 3 | 2024 | 802 | 0.300 |
Why?
|
Cardiac Surgical Procedures | 1 | 2023 | 3627 | 0.290 |
Why?
|
Equipment Contamination | 1 | 2008 | 182 | 0.290 |
Why?
|
Aged, 80 and over | 19 | 2024 | 58976 | 0.290 |
Why?
|
Medical Records Systems, Computerized | 3 | 2014 | 1192 | 0.290 |
Why?
|
Diabetes Mellitus | 3 | 2022 | 5840 | 0.280 |
Why?
|
Exercise | 2 | 2021 | 5890 | 0.280 |
Why?
|
Health Services Research | 2 | 2015 | 1812 | 0.270 |
Why?
|
Young Adult | 17 | 2024 | 59243 | 0.270 |
Why?
|
Early Diagnosis | 3 | 2020 | 1186 | 0.270 |
Why?
|
Boston | 8 | 2021 | 9326 | 0.270 |
Why?
|
Vaccines | 1 | 2015 | 844 | 0.270 |
Why?
|
Cohort Studies | 16 | 2024 | 41487 | 0.270 |
Why?
|
Water | 2 | 2022 | 1411 | 0.260 |
Why?
|
Surgical Procedures, Operative | 3 | 2016 | 1922 | 0.260 |
Why?
|
Reproducibility of Results | 11 | 2023 | 20098 | 0.250 |
Why?
|
Hypertension | 2 | 2023 | 8540 | 0.250 |
Why?
|
Chronic Disease | 4 | 2024 | 9318 | 0.250 |
Why?
|
Antipsychotic Agents | 1 | 2018 | 3067 | 0.250 |
Why?
|
Adrenal Cortex Hormones | 2 | 2021 | 1880 | 0.240 |
Why?
|
Electronics | 2 | 2023 | 318 | 0.240 |
Why?
|
Diagnostic Errors | 3 | 2020 | 1265 | 0.240 |
Why?
|
Primary Health Care | 5 | 2022 | 4686 | 0.240 |
Why?
|
International Classification of Diseases | 3 | 2020 | 909 | 0.230 |
Why?
|
Asthma | 2 | 2024 | 6234 | 0.230 |
Why?
|
Sensitivity and Specificity | 9 | 2020 | 14666 | 0.230 |
Why?
|
Delivery of Health Care | 7 | 2023 | 5336 | 0.230 |
Why?
|
Bacteria | 1 | 2014 | 2199 | 0.220 |
Why?
|
Staphylococcal Infections | 4 | 2023 | 1408 | 0.220 |
Why?
|
Proton Pump Inhibitors | 2 | 2020 | 532 | 0.220 |
Why?
|
Lactic Acid | 5 | 2021 | 1139 | 0.220 |
Why?
|
Hospitals, University | 3 | 2014 | 563 | 0.220 |
Why?
|
Pulmonary Atelectasis | 2 | 2015 | 143 | 0.220 |
Why?
|
Asymptomatic Infections | 2 | 2021 | 131 | 0.210 |
Why?
|
Fluid Therapy | 4 | 2022 | 579 | 0.210 |
Why?
|
Personnel, Hospital | 2 | 2021 | 285 | 0.210 |
Why?
|
Carbapenems | 2 | 2020 | 123 | 0.200 |
Why?
|
Rhinovirus | 1 | 2024 | 203 | 0.200 |
Why?
|
Meta-Analysis as Topic | 2 | 2017 | 1380 | 0.200 |
Why?
|
Severe Acute Respiratory Syndrome | 2 | 2020 | 137 | 0.200 |
Why?
|
Ice | 1 | 2023 | 102 | 0.200 |
Why?
|
Infant, Newborn | 10 | 2023 | 26198 | 0.200 |
Why?
|
England | 1 | 2023 | 526 | 0.200 |
Why?
|
Medical Audit | 4 | 2018 | 453 | 0.200 |
Why?
|
Quality of Health Care | 3 | 2018 | 4330 | 0.200 |
Why?
|
beta-Lactams | 1 | 2023 | 155 | 0.190 |
Why?
|
Azabicyclo Compounds | 2 | 2021 | 68 | 0.190 |
Why?
|
Reimbursement, Incentive | 2 | 2024 | 543 | 0.190 |
Why?
|
Drug Contamination | 1 | 2022 | 152 | 0.190 |
Why?
|
Information Dissemination | 2 | 2023 | 1126 | 0.190 |
Why?
|
Ventilation | 1 | 2021 | 128 | 0.180 |
Why?
|
Patient Positioning | 2 | 2016 | 326 | 0.180 |
Why?
|
Comorbidity | 5 | 2024 | 10508 | 0.180 |
Why?
|
Child, Preschool | 9 | 2024 | 42230 | 0.180 |
Why?
|
Adolescent | 15 | 2024 | 88319 | 0.180 |
Why?
|
Water-Electrolyte Balance | 1 | 2022 | 325 | 0.180 |
Why?
|
Models, Statistical | 1 | 2015 | 5079 | 0.180 |
Why?
|
Rural Health Services | 1 | 2024 | 384 | 0.170 |
Why?
|
Developing Countries | 1 | 2012 | 2885 | 0.170 |
Why?
|
Predictive Value of Tests | 7 | 2020 | 15266 | 0.170 |
Why?
|
Hospitals, Teaching | 3 | 2019 | 1156 | 0.170 |
Why?
|
Obesity | 3 | 2022 | 12947 | 0.170 |
Why?
|
Adenoviridae | 1 | 2024 | 1084 | 0.170 |
Why?
|
Regression Analysis | 3 | 2015 | 6343 | 0.170 |
Why?
|
Sex Factors | 4 | 2024 | 10552 | 0.170 |
Why?
|
Respiration | 2 | 2016 | 1657 | 0.170 |
Why?
|
Immunization, Secondary | 1 | 2022 | 367 | 0.160 |
Why?
|
Catalysis | 1 | 2021 | 774 | 0.160 |
Why?
|
Reference Values | 3 | 2021 | 4920 | 0.160 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2014 | 12148 | 0.160 |
Why?
|
Child | 12 | 2024 | 80153 | 0.160 |
Why?
|
Public Health | 4 | 2023 | 2669 | 0.160 |
Why?
|
Thromboembolism | 2 | 2016 | 995 | 0.160 |
Why?
|
Oxygen | 4 | 2024 | 4227 | 0.160 |
Why?
|
Infant | 10 | 2019 | 36192 | 0.160 |
Why?
|
Histamine H2 Antagonists | 1 | 2020 | 166 | 0.160 |
Why?
|
Prospective Studies | 9 | 2023 | 54425 | 0.160 |
Why?
|
Public Health Administration | 3 | 2015 | 242 | 0.160 |
Why?
|
Peptic Ulcer | 1 | 2020 | 217 | 0.150 |
Why?
|
Seasons | 1 | 2024 | 1520 | 0.150 |
Why?
|
Corynebacterium | 1 | 2018 | 48 | 0.150 |
Why?
|
Corynebacterium Infections | 1 | 2018 | 27 | 0.150 |
Why?
|
Syphilis | 1 | 2021 | 243 | 0.150 |
Why?
|
History, 21st Century | 1 | 2024 | 1567 | 0.150 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2023 | 625 | 0.150 |
Why?
|
Pseudomonas aeruginosa | 2 | 2023 | 1277 | 0.150 |
Why?
|
Logistic Models | 7 | 2021 | 13255 | 0.150 |
Why?
|
Respiratory System | 1 | 2021 | 563 | 0.150 |
Why?
|
Tuberculosis | 1 | 2010 | 2017 | 0.150 |
Why?
|
Diagnosis, Differential | 4 | 2021 | 12974 | 0.150 |
Why?
|
Insurance Claim Reporting | 2 | 2017 | 166 | 0.140 |
Why?
|
Inpatients | 3 | 2024 | 2548 | 0.140 |
Why?
|
Pharmacoepidemiology | 1 | 2021 | 350 | 0.140 |
Why?
|
Vasoconstrictor Agents | 2 | 2021 | 654 | 0.140 |
Why?
|
Drug Resistance, Microbial | 1 | 2020 | 825 | 0.140 |
Why?
|
Amikacin | 1 | 2016 | 47 | 0.140 |
Why?
|
France | 1 | 2018 | 497 | 0.140 |
Why?
|
Treatment Outcome | 11 | 2023 | 64680 | 0.140 |
Why?
|
Population Growth | 1 | 2016 | 50 | 0.130 |
Why?
|
Standard of Care | 1 | 2020 | 551 | 0.130 |
Why?
|
Administration, Oral | 3 | 2023 | 4021 | 0.130 |
Why?
|
Colistin | 1 | 2016 | 44 | 0.130 |
Why?
|
Particle Size | 1 | 2020 | 1648 | 0.130 |
Why?
|
Models, Theoretical | 1 | 2008 | 3575 | 0.130 |
Why?
|
Respiratory Therapy | 1 | 2016 | 125 | 0.130 |
Why?
|
Maryland | 1 | 2016 | 277 | 0.130 |
Why?
|
Patellar Ligament | 1 | 2016 | 64 | 0.130 |
Why?
|
Culture Techniques | 1 | 2016 | 531 | 0.130 |
Why?
|
Drug Combinations | 2 | 2021 | 2048 | 0.130 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2002 | 696 | 0.130 |
Why?
|
Computer Systems | 2 | 2014 | 470 | 0.120 |
Why?
|
Ulcer | 1 | 2016 | 204 | 0.120 |
Why?
|
Acinetobacter Infections | 1 | 2015 | 73 | 0.120 |
Why?
|
Buprenorphine | 1 | 2023 | 656 | 0.120 |
Why?
|
Pennsylvania | 1 | 2016 | 613 | 0.120 |
Why?
|
Coma | 1 | 2018 | 484 | 0.120 |
Why?
|
Ambulatory Care | 2 | 2019 | 2775 | 0.120 |
Why?
|
Sexually Transmitted Diseases | 1 | 2021 | 662 | 0.120 |
Why?
|
Safety Management | 1 | 2020 | 760 | 0.120 |
Why?
|
Ohio | 1 | 2015 | 322 | 0.120 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2022 | 3810 | 0.120 |
Why?
|
Case-Control Studies | 5 | 2022 | 22176 | 0.120 |
Why?
|
Selection Bias | 1 | 2016 | 359 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2023 | 10209 | 0.120 |
Why?
|
Terminology as Topic | 2 | 2019 | 1530 | 0.120 |
Why?
|
Biota | 1 | 2014 | 23 | 0.120 |
Why?
|
Anti-HIV Agents | 2 | 2021 | 4527 | 0.110 |
Why?
|
Sexual Partners | 1 | 2019 | 796 | 0.110 |
Why?
|
Continuity of Patient Care | 1 | 2021 | 1069 | 0.110 |
Why?
|
Cause of Death | 1 | 2024 | 3683 | 0.110 |
Why?
|
Quarantine | 1 | 2016 | 181 | 0.110 |
Why?
|
Occupational Health | 1 | 2020 | 806 | 0.110 |
Why?
|
Hospitals, Special | 1 | 2014 | 91 | 0.110 |
Why?
|
Influenza Vaccines | 1 | 2021 | 768 | 0.110 |
Why?
|
Antihypertensive Agents | 1 | 2023 | 2024 | 0.110 |
Why?
|
Drainage | 2 | 2017 | 1157 | 0.110 |
Why?
|
Microbial Sensitivity Tests | 4 | 2022 | 1937 | 0.110 |
Why?
|
Probiotics | 1 | 2017 | 378 | 0.110 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 3205 | 0.110 |
Why?
|
Antifungal Agents | 2 | 2016 | 752 | 0.110 |
Why?
|
Peroneal Nerve | 1 | 2013 | 76 | 0.110 |
Why?
|
Viral Load | 1 | 2022 | 3332 | 0.110 |
Why?
|
Acute Disease | 3 | 2012 | 7237 | 0.110 |
Why?
|
Administration, Inhalation | 1 | 2016 | 1157 | 0.110 |
Why?
|
HIV | 1 | 2020 | 1582 | 0.110 |
Why?
|
Patient Care Planning | 1 | 2018 | 908 | 0.100 |
Why?
|
Polyarteritis Nodosa | 1 | 2013 | 70 | 0.100 |
Why?
|
Secondary Prevention | 1 | 2019 | 1475 | 0.100 |
Why?
|
Vaccination | 2 | 2022 | 3384 | 0.100 |
Why?
|
Homosexuality, Male | 1 | 2020 | 1334 | 0.100 |
Why?
|
Computer Security | 1 | 2014 | 261 | 0.100 |
Why?
|
Informed Consent | 1 | 2018 | 1008 | 0.100 |
Why?
|
Patient Admission | 2 | 2021 | 1367 | 0.100 |
Why?
|
Odds Ratio | 4 | 2021 | 9646 | 0.100 |
Why?
|
Drug Administration Routes | 2 | 2021 | 150 | 0.100 |
Why?
|
New York | 1 | 2014 | 874 | 0.100 |
Why?
|
Weight Gain | 1 | 2022 | 2348 | 0.100 |
Why?
|
Posture | 1 | 2015 | 957 | 0.090 |
Why?
|
Trust | 1 | 2016 | 530 | 0.090 |
Why?
|
Bone Transplantation | 1 | 2016 | 929 | 0.090 |
Why?
|
Gait Disorders, Neurologic | 1 | 2013 | 240 | 0.090 |
Why?
|
Professional-Patient Relations | 1 | 2016 | 726 | 0.090 |
Why?
|
Area Under Curve | 1 | 2015 | 1638 | 0.090 |
Why?
|
Poisson Distribution | 1 | 2012 | 504 | 0.090 |
Why?
|
Central Nervous System Fungal Infections | 1 | 2010 | 24 | 0.090 |
Why?
|
Liver Function Tests | 1 | 2012 | 523 | 0.090 |
Why?
|
Comparative Effectiveness Research | 1 | 2016 | 709 | 0.090 |
Why?
|
Diagnosis-Related Groups | 1 | 2012 | 449 | 0.090 |
Why?
|
Hair | 1 | 2014 | 498 | 0.090 |
Why?
|
Carrier State | 1 | 2014 | 523 | 0.090 |
Why?
|
Proportional Hazards Models | 4 | 2019 | 12463 | 0.090 |
Why?
|
Equipment and Supplies | 1 | 2012 | 273 | 0.090 |
Why?
|
Ascomycota | 1 | 2010 | 81 | 0.090 |
Why?
|
Silver | 1 | 2010 | 117 | 0.080 |
Why?
|
Epidemiologic Methods | 1 | 2014 | 1336 | 0.080 |
Why?
|
beta-Lactamases | 2 | 2022 | 304 | 0.080 |
Why?
|
Group Practice | 1 | 2010 | 151 | 0.080 |
Why?
|
Multivariate Analysis | 6 | 2020 | 12059 | 0.080 |
Why?
|
Health Care Costs | 2 | 2020 | 3242 | 0.080 |
Why?
|
Documentation | 1 | 2015 | 897 | 0.080 |
Why?
|
Risk | 3 | 2021 | 9610 | 0.080 |
Why?
|
Blood Transfusion | 1 | 2015 | 1298 | 0.080 |
Why?
|
North Carolina | 2 | 2019 | 325 | 0.080 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3358 | 0.080 |
Why?
|
Health Behavior | 2 | 2017 | 2643 | 0.080 |
Why?
|
Age Distribution | 3 | 2019 | 2880 | 0.080 |
Why?
|
Patient Discharge | 3 | 2023 | 3443 | 0.080 |
Why?
|
Immunoglobulins | 2 | 2021 | 853 | 0.080 |
Why?
|
Confidence Intervals | 1 | 2014 | 2927 | 0.080 |
Why?
|
Lung Transplantation | 1 | 2018 | 1310 | 0.080 |
Why?
|
Disinfection | 1 | 2010 | 211 | 0.080 |
Why?
|
Opioid-Related Disorders | 1 | 2023 | 2164 | 0.070 |
Why?
|
Health Maintenance Organizations | 1 | 2010 | 659 | 0.070 |
Why?
|
Urinary Catheterization | 1 | 2008 | 193 | 0.070 |
Why?
|
Patient Care Team | 2 | 2016 | 2521 | 0.070 |
Why?
|
Pregnancy | 2 | 2020 | 29874 | 0.070 |
Why?
|
Risk Assessment | 6 | 2021 | 23995 | 0.070 |
Why?
|
Drug Therapy, Combination | 1 | 2017 | 6310 | 0.070 |
Why?
|
Gentian Violet | 1 | 2007 | 26 | 0.070 |
Why?
|
Review Literature as Topic | 1 | 2009 | 348 | 0.070 |
Why?
|
Attitude to Health | 1 | 2016 | 2025 | 0.070 |
Why?
|
Phenazines | 1 | 2007 | 56 | 0.070 |
Why?
|
ROC Curve | 1 | 2015 | 3579 | 0.070 |
Why?
|
Immunoglobulin M | 1 | 2012 | 1527 | 0.070 |
Why?
|
Resuscitation | 2 | 2021 | 673 | 0.070 |
Why?
|
Immunocompromised Host | 3 | 2019 | 856 | 0.070 |
Why?
|
Recurrence | 1 | 2019 | 8465 | 0.070 |
Why?
|
RNA, Messenger | 1 | 2021 | 12795 | 0.070 |
Why?
|
Survival Analysis | 1 | 2018 | 10090 | 0.060 |
Why?
|
Age Factors | 3 | 2019 | 18395 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39106 | 0.060 |
Why?
|
Transplantation, Homologous | 1 | 2014 | 4806 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2018 | 3600 | 0.060 |
Why?
|
Bacteriological Techniques | 2 | 2016 | 275 | 0.060 |
Why?
|
Data Collection | 1 | 2014 | 3322 | 0.060 |
Why?
|
Anesthesia | 1 | 2015 | 1594 | 0.060 |
Why?
|
Quality Assurance, Health Care | 2 | 2018 | 2169 | 0.060 |
Why?
|
Medical Records | 1 | 2010 | 1408 | 0.060 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 8002 | 0.060 |
Why?
|
Bayes Theorem | 2 | 2024 | 2330 | 0.060 |
Why?
|
Body Mass Index | 3 | 2022 | 12953 | 0.060 |
Why?
|
Biofilms | 1 | 2008 | 628 | 0.060 |
Why?
|
Monobactams | 1 | 2023 | 16 | 0.060 |
Why?
|
Patient Isolators | 1 | 2023 | 11 | 0.060 |
Why?
|
Frontal Lobe | 1 | 2010 | 1420 | 0.060 |
Why?
|
Louisiana | 1 | 2023 | 103 | 0.060 |
Why?
|
Registries | 2 | 2020 | 8224 | 0.060 |
Why?
|
Indiana | 1 | 2023 | 92 | 0.060 |
Why?
|
Catheterization, Central Venous | 1 | 2008 | 527 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2021 | 4853 | 0.050 |
Why?
|
Double-Blind Method | 1 | 2017 | 12341 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5492 | 0.050 |
Why?
|
Insurance, Health | 1 | 2015 | 2498 | 0.050 |
Why?
|
Aspergillus | 1 | 2023 | 93 | 0.050 |
Why?
|
Enterobacter | 1 | 2022 | 44 | 0.050 |
Why?
|
Feasibility Studies | 1 | 2012 | 5247 | 0.050 |
Why?
|
Oseltamivir | 1 | 2022 | 75 | 0.050 |
Why?
|
Myocardial Infarction | 1 | 2022 | 11460 | 0.050 |
Why?
|
Neoplasms | 2 | 2021 | 22170 | 0.050 |
Why?
|
Glucagon | 1 | 2003 | 532 | 0.050 |
Why?
|
Heart Failure | 2 | 2022 | 11669 | 0.050 |
Why?
|
Visitors to Patients | 1 | 2020 | 36 | 0.040 |
Why?
|
Software | 1 | 2014 | 4434 | 0.040 |
Why?
|
Drug Resistance, Bacterial | 2 | 2020 | 1048 | 0.040 |
Why?
|
Acute Kidney Injury | 1 | 2012 | 1924 | 0.040 |
Why?
|
Hospital Bed Capacity | 1 | 2021 | 206 | 0.040 |
Why?
|
Rats | 1 | 2016 | 23742 | 0.040 |
Why?
|
Bronchoalveolar Lavage | 1 | 2020 | 128 | 0.040 |
Why?
|
Longitudinal Studies | 1 | 2016 | 14605 | 0.040 |
Why?
|
Death Certificates | 1 | 2020 | 167 | 0.040 |
Why?
|
Medically Underserved Area | 1 | 2022 | 254 | 0.040 |
Why?
|
Renal Replacement Therapy | 1 | 2021 | 282 | 0.040 |
Why?
|
Bronchitis, Chronic | 1 | 2019 | 82 | 0.040 |
Why?
|
Opiate Substitution Treatment | 1 | 2023 | 444 | 0.040 |
Why?
|
Cardiotonic Agents | 1 | 2021 | 539 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2023 | 2219 | 0.040 |
Why?
|
Gastrointestinal Agents | 1 | 2003 | 510 | 0.040 |
Why?
|
Australia | 1 | 2022 | 1250 | 0.040 |
Why?
|
Mental Disorders | 1 | 2018 | 6845 | 0.040 |
Why?
|
Medical History Taking | 1 | 2002 | 774 | 0.040 |
Why?
|
Paralysis | 1 | 2019 | 250 | 0.040 |
Why?
|
Coronavirus | 1 | 2020 | 154 | 0.040 |
Why?
|
CD4 Lymphocyte Count | 1 | 2024 | 2571 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 1702 | 0.040 |
Why?
|
Disease Management | 2 | 2018 | 2508 | 0.040 |
Why?
|
Plasmids | 1 | 2022 | 2269 | 0.040 |
Why?
|
Gram-Negative Bacteria | 1 | 2018 | 272 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2016 | 18252 | 0.030 |
Why?
|
Erythrocyte Transfusion | 1 | 2021 | 565 | 0.030 |
Why?
|
Fluoroquinolones | 1 | 2018 | 307 | 0.030 |
Why?
|
Skilled Nursing Facilities | 1 | 2021 | 398 | 0.030 |
Why?
|
Genomics | 2 | 2023 | 5821 | 0.030 |
Why?
|
Hypoglycemia | 1 | 2003 | 883 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26125 | 0.030 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2023 | 846 | 0.030 |
Why?
|
Physical Examination | 1 | 2002 | 1255 | 0.030 |
Why?
|
Acinetobacter | 1 | 2015 | 39 | 0.030 |
Why?
|
China | 1 | 2022 | 2369 | 0.030 |
Why?
|
Thinness | 1 | 2019 | 490 | 0.030 |
Why?
|
Radiography, Thoracic | 1 | 2002 | 1302 | 0.030 |
Why?
|
Dexamethasone | 1 | 2023 | 1948 | 0.030 |
Why?
|
Linear Models | 2 | 2018 | 5871 | 0.030 |
Why?
|
Chest Pain | 1 | 2002 | 1091 | 0.030 |
Why?
|
Biomedical Research | 1 | 2010 | 3429 | 0.030 |
Why?
|
Inservice Training | 1 | 2017 | 375 | 0.030 |
Why?
|
Hepatitis, Viral, Human | 1 | 2015 | 141 | 0.030 |
Why?
|
Databases, Factual | 2 | 2020 | 7967 | 0.030 |
Why?
|
Pulmonary Emphysema | 1 | 2019 | 684 | 0.030 |
Why?
|
Animals | 2 | 2016 | 168459 | 0.030 |
Why?
|
Survival Rate | 2 | 2021 | 12725 | 0.030 |
Why?
|
Hepatitis B Core Antigens | 1 | 2013 | 90 | 0.030 |
Why?
|
Intention | 1 | 2016 | 347 | 0.030 |
Why?
|
Surgery Department, Hospital | 1 | 2014 | 176 | 0.030 |
Why?
|
Causality | 1 | 2019 | 1242 | 0.030 |
Why?
|
Staphylococcus aureus | 1 | 2021 | 1458 | 0.030 |
Why?
|
Genome, Bacterial | 1 | 2018 | 783 | 0.030 |
Why?
|
Prognosis | 3 | 2019 | 29625 | 0.030 |
Why?
|
Stress, Physiological | 1 | 2020 | 1403 | 0.030 |
Why?
|
Culture | 1 | 2016 | 623 | 0.030 |
Why?
|
Automation | 1 | 2014 | 586 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2020 | 1886 | 0.020 |
Why?
|
Neural Conduction | 1 | 2013 | 441 | 0.020 |
Why?
|
Oral Health | 1 | 2017 | 492 | 0.020 |
Why?
|
Sex Distribution | 1 | 2016 | 2281 | 0.020 |
Why?
|
Glucose | 1 | 2003 | 4346 | 0.020 |
Why?
|
Hemodynamics | 1 | 2021 | 4159 | 0.020 |
Why?
|
Pilot Projects | 1 | 2024 | 8631 | 0.020 |
Why?
|
Intensive Care Units, Pediatric | 1 | 2017 | 1017 | 0.020 |
Why?
|
Muscle Weakness | 1 | 2013 | 412 | 0.020 |
Why?
|
Cost of Illness | 1 | 2019 | 1936 | 0.020 |
Why?
|
beta-Glucans | 1 | 2010 | 123 | 0.020 |
Why?
|
Program Evaluation | 1 | 2018 | 2495 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3060 | 0.020 |
Why?
|
Histocytochemistry | 1 | 2010 | 698 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6484 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2018 | 1886 | 0.020 |
Why?
|
Bacterial Proteins | 1 | 2022 | 3847 | 0.020 |
Why?
|
Education, Medical, Continuing | 1 | 2014 | 823 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4244 | 0.020 |
Why?
|
Morbidity | 1 | 2013 | 1750 | 0.020 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2015 | 832 | 0.020 |
Why?
|
California | 1 | 2011 | 1429 | 0.020 |
Why?
|
Mental Health | 1 | 2022 | 3250 | 0.020 |
Why?
|
Blood Glucose | 1 | 2021 | 6391 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2023 | 3808 | 0.020 |
Why?
|
Urban Population | 1 | 2014 | 2036 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2021 | 4016 | 0.020 |
Why?
|
Mortality | 1 | 2017 | 2901 | 0.020 |
Why?
|
Fever | 1 | 2013 | 1618 | 0.020 |
Why?
|
Phenotype | 1 | 2023 | 16591 | 0.020 |
Why?
|
Microscopy | 1 | 2010 | 903 | 0.020 |
Why?
|
Triazoles | 1 | 2010 | 903 | 0.020 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2015 | 1188 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2011 | 2707 | 0.010 |
Why?
|
Coronary Artery Bypass | 1 | 2013 | 2188 | 0.010 |
Why?
|
Injections, Subcutaneous | 1 | 2003 | 681 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2014 | 7827 | 0.010 |
Why?
|
Natural Language Processing | 1 | 2008 | 1162 | 0.010 |
Why?
|
Radiography | 1 | 2010 | 6965 | 0.010 |
Why?
|
Pyrimidines | 1 | 2010 | 3028 | 0.010 |
Why?
|
Pain | 1 | 2013 | 5073 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2010 | 4174 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2008 | 3688 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2010 | 4234 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2010 | 36426 | 0.000 |
Why?
|